Risankizumab vs Ustekinumab for Psoriasis
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=uSZPplfbyGI
Ustekinumab, which targets a subunit of IL-23, has shown efficacy and safety in patients with psoriasis. But is there a more effective IL-23 inhibitor? New research findings are summarized in this short video. Full study: http://nej.md/2os6I29
#############################
